Locations:
Search IconSearch
January 2, 2024/Cancer/Surgical Oncology

Exploring Focal Therapies for Prostate Cancer (Podcast)

Patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Cancer therapies treat the entire prostate. But for a subset of patients, minimally invasive focal therapies that leave part of the prostate untreated may be an option. “[The key is] finding men who are intermediate risk, who based on imaging and based on biopsies have cancer localized to one small part of their prostate,” says Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic.

In a recent episode of Cleveland Clinic’s Cancer Advances podcast, Dr. Schwen discusses focal therapy for prostate cancer. He covers:

  • The difference between traditional treatments and focal therapies
  • Factors that make a patient a good candidate for focal therapy
  • Focal procedures, including Nanoknife, high-intensity focused ultrasound and cryotherapy
  • Risk of recurrence and salvage therapies
  • Clinical trials devoted to focal therapies

Click the podcast player above to listen to the episode now, or read on for a short edited excerpt.

Check out more Cancer Advances episodes at my.clevelandclinic.org/podcasts/cancer-advances or wherever you get your podcasts.

Excerpt from the podcast:

Podcast host Dale Shepard, MD, PhD: Let’s talk a little bit about what these procedures are, what these focal therapies are. Tell us a little bit about Nanoknife.

Dr. Schwen: This is a newer technology, a newer energy of what we call electroporation. What we do is we deliver high voltage current across the prostate tissue, usually in the form of a needle that disrupts the cell membrane of the cancer cell and then causes cell death. And so, they call it electroporation.

Advertisement

Essentially, it creates pores in the cell membrane, and then as a result, the cell dies. And what’s good about Nanoknife, which is the term that people use, is that it can be directed in a focal way, but also it reduces the collateral damage of the normal tissue around it. So, it has less collateral damage than some of the other energies that we have.

Another advantage of [Nanoknife] is that we can deliver it to other parts of the prostate that were
difficult to reach with other focal therapies, like the anterior prostate. The top of the prostate
traditionally was difficult to reach with some of our other focal therapies like HIFU, which is an
ultrasound ablation, and a lot of these have to be directed through the rectum. So, reaching the top of
the prostate is sometimes more challenging, and sometimes the urethra is in the way. The Nanoknife is another type of energy that allows us to deliver that energy to a focal part of the prostate at the top
that would be difficult to reach with HIFU.

Advertisement

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024/Cancer/Blood Cancers
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024/Cancer
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

Ad